Redeye is glad to see that LKAB has returned with a new major contract for ore transports.
Redeye is encouraged by today’s news that Amniotic’s phase I/II trial with Pulmostem has been approv...
Redeye is encouraged by today’s news that Annexin’s phase II trial is approved to start in the US as...
Mot ny inriktning med färskt kapitaltillskott Loudspring fortsatte sin strategiska omställning mot e...
iZafe, utvecklaren av läkemedeldispenseringsautomaten Dosell, har under mars 2022 lanserat konsument...
Carlsquare Equity Research ser positivt på utnämningen av Anna Linton (tidigare Unimedic/MedCap) som...
Redeye comments on yesterday’s news from Paynova, where the company announced a fully secured rights...
We give a short comment on the news that Annexin Pharmaceuticals has in-licensed a patent related to...
Under förra veckan kommunicerade Transfer att det helägda dotterbolaget CSG dels tecknat ett treårig...
Redeye believes that today's announcement involves Sony, which means that the customer launch holds ...
Fortsatt utrullning av ramavtal borde ge stöd till försäljningen Trots att tillväxttakten i slutet a...
Volymerna framskjutna på grund av de försenade borrningarna… Även om resultaten för borrningen av Ti...
Soltech har haft en intensiv period med nya ordrar och flera förvärv.
Zesec of Sweden (Zesec), utvecklar digitala nycklar till mobilen.
Redeye initiates coverage of Ultimovacs, a Nordic biotech company developing therapeutic cancer vacc...
Redeye endorses aXichem applying for Feed Additive in the EU and views this as an important mileston...
CirChem publicerade igår den 31 mars 2021 sin delårsrapport för fjärde kvartalet 2021.
Administer reported H2 results and a gave a guidance that were well in line with our expectations an...
Redeye comments on Invisio’s announcement of three large orders which confirms our view of strong gr...
IRLAB’s inaugural capital markets day outlined the depth of its expanding pipeline and the catalysts...
